|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Series C Preferred Stock | (1) | 05/13/2014 | C | 2,083,541 | (1) | (1) | Common Stock | 2,083,541 | $ 0 (1) | 0 | I | By Delphi Ventures VII, L.P. (2) | |||
Series D Preferred Stock | (1) | 05/13/2014 | C | 380,353 | (1) | (1) | Common Stock | 380,353 | $ 0 (1) | 0 | I | By Delphi Ventures VII, L.P. (2) | |||
Series C Preferred Stock | (1) | 05/13/2014 | C | 20,835 | (1) | (1) | Common Stock | 20,835 | $ 0 (1) | 0 | I | By Delphi BioInvestments VII, L.P. (3) | |||
Series D Preferred Stock | (1) | 05/13/2014 | C | 3,803 | (1) | (1) | Common Stock | 3,803 | $ 0 (1) | 0 | I | By Delphi BioInvestments VII, L.P. (3) |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Delphi Management Partners VII, L.L.C. C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG. 1, SUITE 135 MENLO PARK, CA 94025 |
X | |||
DELPHI VENTURES VII L P 3000 SAND HILL ROAD BUILDING 1, SUITE 135 MENLO PARK, CA 94025 |
X | |||
DELPHI BIOINVESTMENTS VII LP 3000 SAND HILL ROAD BUILDING 1, SUITE 135 MENLO PARK, CA 94025 |
X | |||
PAKIANATHAN DEEPIKA C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG 1, SUITE 135 MENLO PARK, CA 94025 |
X | X | ||
ROEDER DOUGLAS A C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG., SUITE 135 MENLO PARK, CA 94025 |
X | |||
DOUGLASS DAVID L C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG. 1, SUITE 135 MENLO PARK, CA 94025 |
X | |||
BOCHNOWSKI JAMES J C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG. 1, SUITE 135 MENLO PARK, CA 94025 |
X |
By /s/ Matthew T. Potter, Attorney-in-Fact for: Delphi Management Partners VII, L.L.C. Delphi Ventures VII, L.P. Delphi BioInvestments VII, L.P. Deepika R. Pakianathan Douglas A. Roder David L. Douglass James J. Bochnowski | 05/13/2014 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | The preferred stock converted into common stock on a 1-for-1 basis upon the closing of the issuer's initial public offering and had no expiration date. |
(2) | The reported securities are directly owned by Delphi Ventures VII, L.P. ("DV VII). DMP VII is the general partner of DV VII and may be deemed to have sole voting and dispositive power over the securities held by DV VII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VII and may be deemed to share voting and dispositive power over the securities held by DV VII. Such persons and entities disclaim beneficial ownership of the securities held by DV VII, except to the extent of any pecuniary interest therein. |
(3) | The reported securities are directly owned by Delphi BioInvestments VII, L.P. ("DBI VII). DMP VII is the general partner of DBI VII and may be deemed to have sole voting and dispositive power over the securities held by DBI VII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VII and may be deemed to share voting and dispositive power over the securities held by DBI VII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VII, except to the extent of any pecuniary interest therein. |